Teva Pharmaceuticals' efforts to cut costs by making its manufacturing more efficient have landed at a plant in the U.K. where the generics leader will cut dozens of jobs but add some new positions with more specialized skills.
Novartis has rid itself of more than two dozen manufacturing sites in the past few years, closing or selling some facilities and handing off a bunch to GlaxoSmithKline as part of their big asset swap. Now the Swiss drugmaker says it intends to organize what is left into one overreaching operation in expectation of saving some serious money by 2020.
Sagent Pharmaceuticals jumped into the sterile injectables manufacturing arena a decade ago, concentrating on high-demand generics but relying on a network of dozens of contractors to source its ingredients and get its finished products. Now, with evaluations high but margins getting thinner, it is thinking about cashing out.
POPULAR COMMENT THREADS
It has been another tough week for some of India's troubled drugmakers. Wockhardt, which has two plants banned by the FDA, saw its hopes stymied for getting export approval for a different facility that it had hoped could help it recoup some of its lost U.S. revenues. And India's Ipca Laboratories, which has three plants on the import alert list, said Monday it has now gotten a warning letter for the facilities.
Valeant's Bausch + Lomb has voluntarily initiated a massive recall of an eye dilation med after learning that more than 1 million bottles may have been shipped with the wrong medication insert.
Sanofi says it intends to apply its decades of vaccine development work and manufacturing expertise in dengue fever to try to create a vaccine for Zika virus, the mosquito-borne disease that the World Health Organization this week called a global health emergency.
India's Ipca Laboratories is facing FDA regulatory actions at plants in India, but the drugmaker's small-scale API and CRO operation in the U.K. intends to again increase capacity, this time by about 30%.
Ever wonder where the websites selling unapproved and sometimes counterfeit drugs get those products? According to the Department of Justice, many of them came from a Pakistani man and his company, JNS Impex.
Sanofi is looking to trim 600 jobs in France as part of new CEO Olivier Brandicourt's plan to squeeze €1.5 billion in annual costs. The drugmaker says it does not plan on closing any plants in France as part of the process, but that does not mean that its production network in the home country will escape unscathed. Brandicourt has also said he will "reshape" the manufacturing network as part of his overall reorganization of the company.
From Our Sister Sites
Thanks to flailing pharma revenues and its decision to ship away its oncology assets, GlaxoSmithKline has a lot riding on vaccines. And in 2015, the unit delivered with 19% revenue growth, although profit and operating margin both fell.
Last fall, veterinary students at Cornell University were the stars of a reality show on Nat Geo WILD called Vet School. Now Cornell's East Coast neighbor, the University of Pennsylvania, is gearing up for its own reality show spotlighting the rigors and adventures of learning to be a veterinarian.